Respirology Search
Respirology Respirology
tonsillopharyngitis%20-%20acute
TONSILLOPHARYNGITIS - ACUTE
Patients with group A beta-hemolytic streptococcal pharyngitis have classic symptoms of tonsillar swelling/exudates, tender anterior cervical lymphadenopathy, with no cough but with fever of >38ºC.
Clinical features suggestive of a viral etiology are conjunctivitis, absence of fever, coryza, cough, diarrhea, anterior stomatitis, hoarseness, discrete ulcerative lesions, rhinorrhea and viral exanthem and/or enanthem.
Antibiotics will not be needed for every patient that presents with sore throat but it should not be withheld if the clinical condition is severe or group A beta-hemolytic streptococcus is suspected.

Tonsillopharyngitis%20-%20acute Patient Education

Patient Education

  • Provide educational material about non-streptococcal causes of sore throats and home remedies that the patient may use
  • Patient should be instructed to follow up if the symptoms worsen or if they persist beyond 5-7 days
  • Advise patient to eliminate close contact with other people to minimize transmission of the disease
    • Patients are infectious 2-5 days before symptom onset, during the illness, and for a week after if untreated

Group A Beta-Hemolytic Streptococci Suspected or Confirmed

  • Instruct the patient to remain at home until at least 24 hours of antimicrobial therapy has been received to minimize transmission of disease
  • Emphasize the importance of adhering to the prescribed medication regimen
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Ivermectin improves survival in COVID-19 patients with severe pulmonary involvement
21 Nov 2020
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
COVID-19 vaccine: A saviour, at last?
Pearl Toh, 19 Dec 2020
With the release of the latest interim efficacy results for ChAdOx1 nCoV-19, the adenovirus-vectored vaccine against COVID-19 is inching a step closer towards regulatory approval — and eventually, widespread use that will hopefully put an end to the relentless carnage by the pandemic.
Having asthma or allergy does not increase risk for severe COVID-19
Elvira Manzano, 12 Dec 2020
Having asthma or allergy does not make COVID-19 severe, a new study presented at ACAAI 2020 has shown.
Global race for COVID-19 vaccine gains momentum
Elvira Manzano, 04 Aug 2020
The global race for a COVID-19 vaccine moves at an unprecedented speed, buoyed by public pressure and geopolitical crosscurrents that were punctuated by deaths and infections around the world.